Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (Q49350947)

20 February 2018

title

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (English)

1 reference

20 February 2018

0 references

0 references

Andrea Navarria

6

0 references

author name string

Richard E Pratley

1

1 reference

20 February 2018

Vanita R Aroda

2

1 reference

20 February 2018

Ildiko Lingvay

3

1 reference

20 February 2018

Jörg Lüdemann

4

1 reference

20 February 2018

Camilla Andreassen

5

1 reference

20 February 2018

Adie Viljoen

7

1 reference

20 February 2018

SUSTAIN 7 investigators

8

1 reference

20 February 2018

publication date

31 January 2018

1 reference

20 February 2018

The Lancet: Diabetes & Endocrinology

published in

1 reference

20 February 2018

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Body-mass index and mortality among adults with incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Mode of administration of dulaglutide: implications for treatment adherence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Guideline for management of postmeal glucose in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

A graphical approach to sequentially rejective multiple test procedures

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Integrating Randomized Comparative Effectiveness Research with Patient Care

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930024-X

7 January 2021

10.1016/S2213-8587(18)30024-X

Identifiers

DOI

1 reference

20 February 2018

1 reference

20 February 2018